Drug discovery: selecting the optimal approach Export

@article{citeulike:3009089, abstract = {The target-based drug discovery approach has for the past 10-15 years been the dominating drug discovery paradigm. However, within the past few years, the commercial value of novel targets in licensing deals has fallen dramatically, reflecting that the probability of reaching a clinical drug candidate for a novel target is very low. This has naturally led to questions regarding the success of target-based drug discovery and, more importantly, a search for alternatives. This paper evaluates the strengths and limitations of the main drug discovery approaches, and proposes a novel approach that could offer advantages for the identification of disease-modifying treatments.}, author = {Sams-Dodd, Frank}, citeulike-article-id = {3009089}, citeulike-linkout-0 = {http://dx.doi.org/10.1016/j.drudis.2006.03.015}, citeulike-linkout-1 = {http://www.sciencedirect.com/science/article/B6T64-4JSMRWG-J/1/fc72ee5f07d497c608c001b824494281}, doi = {10.1016/j.drudis.2006.03.015}, journal = {Drug Discovery Today}, keywords = {drug\_discovery\_approaches}, month = {May}, number = {9-10}, pages = {465--472}, posted-at = {2008-07-16 18:33:29}, priority = {2}, title = {Drug discovery: selecting the optimal approach}, url = {http://dx.doi.org/10.1016/j.drudis.2006.03.015}, volume = {11}, year = {2006} }

TY - JOUR ID - citeulike:3009089 L3 - citeulike-article-id:3009089 N2 - The target-based drug discovery approach has for the past 10-15 years been the dominating drug discovery paradigm. However, within the past few years, the commercial value of novel targets in licensing deals has fallen dramatically, reflecting that the probability of reaching a clinical drug candidate for a novel target is very low. This has naturally led to questions regarding the success of target-based drug discovery and, more importantly, a search for alternatives. This paper evaluates the strengths and limitations of the main drug discovery approaches, and proposes a novel approach that could offer advantages for the identification of disease-modifying treatments. IS - 9-10 JF - Drug Discovery Today EP - 472 TI - Drug discovery: selecting the optimal approach VL - 11 SP - 465 KW - drug_discovery_approaches AU - Sams-Dodd, Frank PY - 2006/05// UR - http://dx.doi.org/10.1016/j.drudis.2006.03.015 ER -